Celltrion has received permission from the Food and Drug Administration for Stoboclo (CT-P41, denosumab-bmwo) and Osenvelt (CT-P41, denosumab-bmwo), biosimilars referencing Prolia (denosumab) and ...
Shanghai Henlius Biotech and Organon have received permission from the Food and Drug Administration for Bildyos (denosumab-nxxp) injection 60 mg/ml and Bilprevda (denosumab-nxxp) injection 120 mg/1.7 ...
"The approval of STOBOCLO and OSENVELT is another step forward in our efforts to deliver cost-effective and high-quality treatments that address critical unmet needs in osteoporosis-related fracture ...
Stoboclo and Osenvelt, biosimilars of Prolia and Xgeva, are approved for various cancer-related bone conditions, offering cost-effective alternatives. FDA approval confirms therapeutic equivalence of ...
Lynozyfic received accelerated approval for relapsed multiple myeloma, showing a 70% response rate but with notable side effects, including cytokine release syndrome and neurologic toxicity. Zegfrovy ...
BENGALURU, India and BRIDGEWATER, N.J., Sept. 17, 2025 /PRNewswire/ -- Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of ...
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), a global biopharmaceutical company, and mAbxience ...
BENGALURU, India and BRIDGEWATER, N.J., Oct. 1, 2025 /PRNewswire/ -- Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE: 532523, NSE: BIOCON) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback